Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
$4.25M+14.7%$3.71M+14.9%$3.23M+18.1%$2.73M+26.1%$2.17M+15.9%
$5.9M-1.8%$6.01M+4.0%$5.78M+7.8%$5.36M+13.9%$4.71M+15.9%
$10.15M+4.5%$9.72M+7.9%$9M+11.2%$8.09M+17.7%$6.87M+15.9%
-$10.15M-4.5%-$9.72M-7.9%-$9M-11.2%-$8.09M-17.7%-$6.87M-15.9%
$281.5K-22.3%$362.09K+55.3%$233.23K+6.6%$218.69K+94.6%$112.36K+44.8%
-$9.78M-5.5%-$9.26M-11.1%-$8.34M-8.2%-$7.71M-14.9%-$6.71M-14.5%
-$105.21K
-$9.67M-5.6%-$9.16M-9.8%-$8.34M-8.2%-$7.71M-14.9%-$6.71M-14.5%
-$1.14-5.6%-$1.08-5.9%-$1.020.0%-$1.02-6.3%-$0.96-6.7%
-$9.86M-4.6%-$9.43M-8.1%-$8.72M-11.6%-$7.81M-18.4%-$6.6M-16.5%
-$10.15M-4.5%-$9.72M-7.9%-$9M-11.2%-$8.09M-17.7%-$6.87M-15.9%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What is eXoZymes Inc. Common Stock's revenue?
eXoZymes Inc. Common Stock (EXOZ) generated $70.1K in revenue over the trailing twelve months.
Is eXoZymes Inc. Common Stock profitable?
eXoZymes Inc. Common Stock is not currently profitable: it reported a net loss of $9.7M over the trailing twelve months, a -2909.1% net margin.
What is eXoZymes Inc. Common Stock's earnings per share?
eXoZymes Inc. Common Stock's diluted EPS over the trailing twelve months is $-1.14.
Where does eXoZymes Inc. Common Stock's income statement data come from?
Every line is extracted from eXoZymes Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.